Tests obinutuzumab in adults with diffuse systemic sclerosis
Tests obinutuzumab against a placebo in adults with diffuse systemic sclerosis.
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- Amiens Cedex 1, Angers, Angouleme Cedex 9, Avignon, Bobigny Cedex, Bordeaux, Caen, Clermont-Ferrand, Contamine-sur-Arve, Creteil Cedex, Dax, Dijon, Le Kremlin-Bicetre, Le Mans Cedex 9, Lille, Limoges, Lomme Cedex, Marseille, Montivilliers, Nantes, Nice, Niort, Orleans Cedex 2, Paris, Paris Cedex 10, Perpignan Cedex, Reims Cedex, Rennes, Rouen, Saint-Priest-en-Jarez, Strasbourg Cedex, Strasbourg Cedex 2, Toulon Cedex 9, Toulouse, Tours, Valenciennes, Vandoeuvre Les Nancy, and Vantoux, FranceSee the 38 sites
- Trial code
- Registry title
- OBINUSS - A trial to evaluate a new drug in systemic sclerosis: obinutuzumab.
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 74 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 1 Jan 2030
- Type of study
- Interventional
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with diffuse systemic sclerosis who have had the disease for less than 8 years or have active disease. It tests obinutuzumab against a placebo.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Diffuse systemic sclerosis (SSc), with disease duration under 8 years or active disease, and a modified Rodnan skin score of 10 to 35 at screening
- Earlier treatment
- If taking mycophenolate or methotrexate for SSc, the dose must be stable for at least 2 months before randomisation. Nintedanib is permitted. No B-cell depleting therapy such as rituximab in the 9 months before screening. No JAK, BTK or TYK2 inhibitors, other biologic therapy, cyclophosphamide, tacrolimus, ciclosporin or voclosporin in the 2 months before screening. No CAR-T cell therapy.
Main reasons for not taking part
- Active infection, or a history of serious recurrent or chronic infection
- Cancer within the past 5 years (treated skin carcinomas excepted)
- Positive hepatitis B surface antigen, positive hepatitis C serology without the allowed conditions, or HIV infection
- Pregnant or breastfeeding women, or women who refuse effective contraception
- Severe allergy to monoclonal antibodies, or past progressive multifocal leukoencephalopathy
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- 1-Adult patient (>/= 18 years old),
- 10- Anti-fibrotic drugs such as nintedanib is permitted
- 2-Patient with a diagnosis of SSc, as defined by the American College of Rheumatology / EULAR 2013 criteria,
- 3-Patient with a diffuse SSc, as defined according to Leroy et al
- 4-Patient with a SSc disease duration of less than 8 years (defined as time from first non-Raynaud phenomenon manifestation) or with an active SSc disease, as defined by EUSTAR disease activity score,
- 5- Patient with a modified Rodnan skin score (mRSS) > /= 10 and < /= 35 units at screening,
- 6-Negative pregnancy test for woman of childbearing potential, woman of childbearing potential should have reliable contraception during the treatment period and up to 18 months after stopping it
- 7-Patient able to give written informed consent prior to participation in the study,
- 8-Affiliation to a social security scheme (profit or being entitled)
- 9- If patients receive mycophenolate or methotrexate for SSc, these need to be on stable dose as follows: Mycophenolate mofetil/sodium: stable dose for at least 2 months prior to randomisation Methotrexate: stable dose and route of administration for at least 2 months prior to randomisation
Who cannot take part
- 10-Active infection of any kind, excluding fungal infection of the nail beds. Any major episode of infection that also fulfills any of the following criteria: * Requires hospitalization during the 8 weeks prior to screening or during screening * Requires treatment with IV antibiotics (or anti-infectives) during the 8 weeks prior to screening or during screening * Requires treatment with oral antibiotics (or anti-infectives) during the 2 weeks prior to screening or during screening * Antibiotics or anti-infectives given in the absence of a major episode of infection are not exclusionary
- 14-Major surgery requiring hospitalization during the 4 weeks prior to or during screening
- 15-Current alcohol or drug abuse or history of alcohol or drug abuse within 12 months prior to screening or during screening
- 2-Cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening
- 21- Patients treated with CAR-T cell immunotherapy
- 3-Any biologic therapy (other than anti-CD20, anti-CD19, or anti-plasma cell) such as, but not limited to, belimumab, ustekinumab, anifrolumab, secukinumab, or atacicept during the 2 months prior to screening or during screening
- 4-Inhibitors of Janus-associated kinase (JAK), Bruton’s tyrosine kinase (BTK), or tyrosine kinase 2 (TYK2), including baricitinib, tofacitinib, upadacitinib, filgotinib, ibrutinib, or fenebrutinib or any investigational agent during the 2 months prior to screening or during screening
- 5-Any live vaccine during the 28 days prior to screening or during screening
- 6-High risk for clinically significant bleeding or any condition requiring plasmapheresis, IV immunoglobulin, or acute blood product transfusions during the 28 days prior the screening
- 11-History of serious recurrent or chronic infection
- 12-History of progressive multifocal leukoencephalopathy (PML)
- 13-History of cancer, including solid tumors, hematological malignancies, and carcinoma in situ, within the past 5 years (Participants with non-melanomatous carcinomas of the skin that have been treated or excised and have resolved are eligible)
- 16-Intolerance or contraindication to study therapies, including any of the following: *History of severe allergic or anaphylactic reactions to monoclonal antibodies or known hypersensitivity to any component of the obinutuzumab infusion
- 7-Active infection with SARS-CoV-2 or patients not fully vaccinated following national recommendations against SARS-CoV-2
- 8-Significant or uncontrolled medical disease which, in the investigator’s opinion, would preclude patient participation
- 9-HIV infection: for participants with unknown HIV status, HIV testing will be performed locally at screening if required by local regulations
- 1-Any B-cell depleting (e.g., anti-CD20, anti-CD19) or anti-plasma cell therapy such as, but not limited to, obinutuzumab, rituximab, ocrelizumab, ofatumumab, or bortezomib less than 9 months prior to screening or during screening. If anti-CD20 or anti-CD19 therapy has been received between 9 and 12 months prior to screening, the peripheral CD19+ B-cell count must be over 25 cells/µL
- 17-Any of the following laboratory parameters: *AST or ALT above 2.5 upper limit normal range * Neutrophils <1.5x103/mL * Positive hepatitis B surface antigen (HBsAg) Participants who are HBsAg negative and hepatitis B core antibody (HBcAb) positive with no detectable hepatitis B virus (HBV) DNA are eligible but will require monthly HBV DNA monitoring until 12 months after the last dose of obinutuzumab or placebo. * Positive hepatitis C serology Participants with positive hepatitis C antibody test result with no detectable hepatitis C virus (HCV) RNA for at least 6 months after completion of antiviral therapy are eligible but will require monthly HCV RNA monitoring until 12 months after the last dose of obinutuzumab or placebo. * Hemoglobin below 7 g/dL * Platelet count below 50,000/L
- 18-Pregnant or breastfeeding woman, or woman who refuses to use an effective contraception during the study course
- 19-Protected adults (including individual under legal guardianship by court order or curatorship) or adults deprived of liberty
- 20-Patient participating in another investigational therapeutic study in the 3 months preceding inclusion
Where in France
- Centre Hospitalier Universitaire Amiens PicardieAmiens Cedex 1, FranceNot yet recruiting
- Centre Hospitalier Universitaire D'AngersAngers, FranceNot yet recruiting
- Centre Hospitalier D AngoulemeAngouleme Cedex 9, FranceNot yet recruiting
- Centre Hospitalier d'AvignonAvignon, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisBobigny Cedex, FranceNot yet recruiting
- Centre hospitalier Universitaire de BordeauxBordeaux, FranceNot yet recruiting
- Centre Hospitalier Universitaire de Caen NormandieCaen, FranceNot yet recruiting
- Centre Jean PerrinClermont-Ferrand, FranceNot yet recruiting
- Centre Hospitalier Alpes LemanContamine-sur-Arve, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisCreteil Cedex, FranceNot yet recruiting
- Centre Hospitalier De Dax Cote D'ArgentDax, FranceNot yet recruiting
- Centre Hospitalier Universitaire de DijonDijon, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisLe Kremlin-Bicetre, FranceNot yet recruiting
- Centre Hospitalier Le MansLe Mans Cedex 9, FranceNot yet recruiting
- Centre Hospitalier Universitaire de LilleLille, FranceNot yet recruiting
- Centre Hospitalier Et Universitaire de LimogesLimoges, FranceNot yet recruiting
- Groupement Des Hopitaux De L'Institut Catholique De LilleLomme Cedex, FranceNot yet recruiting
- Centre Hospitalier Regional De MarseilleMarseille, FranceNot yet recruiting
- Groupe Hospitalier Du HavreMontivilliers, FranceNot yet recruiting
- Centre Hospitalier Universitaire de NantesNantes, FranceNot yet recruiting
- Centre Hospitalier Universitaire de NiceNice, FranceNot yet recruiting
- Centre Hospitalier de NiortNiort, FranceNot yet recruiting
- Centre Hospitalier Universitaire D OrleansOrleans Cedex 2, FranceNot yet recruiting
- Assistance Publique Hopitaux de ParisParis, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisParis Cedex 10, FranceNot yet recruiting
- Centre Hospitalier De PerpignanPerpignan Cedex, FranceNot yet recruiting
- Centre Hospitalier Universitaire ReimsReims Cedex, FranceNot yet recruiting
- Centre Hospitalier Universitaire de RennesRennes, FranceNot yet recruiting
- Centre Hospitalier Universitaire RouenRouen, FranceNot yet recruiting
- Centre Hospitalier Universitaire de Saint EtienneSaint-Priest-en-Jarez, FranceNot yet recruiting
- Les Hopitaux Universitaires De StrasbourgStrasbourg Cedex, FranceNot yet recruiting
- Les Hopitaux Universitaires De StrasbourgStrasbourg Cedex 2, FranceNot yet recruiting
- Direction Centrale Du Service De Sante Des ArmeesToulon Cedex 9, FranceNot yet recruiting
- Centre Hospitalier Universitaire de ToulouseToulouse, FranceNot yet recruiting
- Centre Hospitalier Régional Universitaire de ToursTours, FranceNot yet recruiting
- Centre Hospitalier de ValenciennesValenciennes, FranceNot yet recruiting
- CHRU De NancyVandoeuvre Les Nancy, FranceNot yet recruiting
- Hopitaux Prives De MetzVantoux, FranceNot yet recruiting
About the trial
What the trial wants to find out
The main objective of this study is to show a decrease of both skin and lung fibrosis, as evaluated by the revised Composite Response Index in SSc, 360 days from randomisation, in patients with diffuse SSc treated with obinutuzumab when compared to patients treated with a placebo.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- OBINUSS - Safety and efficacy of obinutuzumab in systemic sclerosis: a phase II, randomized, double-blinded versus placebo-controlled trial
- Plain-language title
- Tests obinutuzumab in adults with diffuse systemic sclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 12 November 2026